Marksans Pharma: Business Overview & Financial Analysis
Marksans Pharma is an Indian pharmaceutical manufacturing enterprise headquartered in Mumbai, Maharashtra. Promoted by Mark Saldanha, the company specializes in the research, development, formulation, and commercialization of generic active pharmaceutical formulations across regulated global markets. Operating state-of-the-art processing plants in India, the United Kingdom, and the United States, Marksans Pharma manufactures over-the-counter (OTC) and prescription (Rx) solid oral dosage forms, soft-gelatin capsules, liquids, and ointments across key therapeutic categories including pain management, cough and cold, central nervous system, cardiovascular, and anti-diabetic care.
Geographic Revenue Mix of Marksans Pharma (FY2026)
Marksans Pharma generates over 95% of its operational revenues from regulated international healthcare markets, led by the United Kingdom and North America.
- UK & Europe Geography Share – 43.5% of Total Operating Revenue
- US & North America Geography Share – 41.2% of Total Operating Revenue
- Australia & New Zealand (ANZ) Geography Share – 10.8% of Total Operating Revenue
- Rest of the World (RoW) Geography Share – 4.5% of Total Operating Revenue
- Total Consolidated Revenue from Operations (FY2026) – Rs 2,485.40 crore (+18.2% YoY)
The United Kingdom and Europe division serves as the primary revenue contributor, supported by direct distribution to retail pharmacy chains and National Health Service (NHS) procurement channels. North American operations deliver high-volume OTC liquid and soft-gelatin capsule sales through major US retail chains.
Product Portfolio & Channel Mix of Marksans Pharma (FY2026)
Marksans Pharma balances its formulation portfolio across over-the-counter (OTC) consumer healthcare products and prescription (Rx) medicines.
- Over-The-Counter (OTC) Products Share – 58.0% of Total Operating Revenue
- Prescription (Rx) Formulations Share – 42.0% of Total Operating Revenue
- Solid Oral Dosage Forms (Tablets & Hard Capsules) – 62.0% of Total Revenue
- Soft-Gelatin Capsules & Liquids – 28.0% of Total Revenue
- Ointments & Other Dosage Forms – 10.0% of Total Revenue
Over-the-counter consumer healthcare products generate nearly six-tenths of operational turnover, providing stable gross margins and low regulatory pricing pressure. Solid oral dosage forms and soft-gelatin capsules form the core manufacturing volume base across overseas markets.
Global Manufacturing Infrastructure & USFDA Approvals of Marksans Pharma (FY2026)
Marksans Pharma operates four specialized formulation plants equipped with high-speed tableting, liquid filling, and soft-gelatin encapsulation lines.
- Operational Manufacturing Plants Base – 4 integrated formulation facilities globally
- Domestic Manufacturing Units – Verna (Goa) and Tevha (Plot No. 1, Goa - former Relonchem asset)
- Primary Overseas Facilities – Southport (United Kingdom) and Farmingdale (New York, USA)
- USFDA Approval Status – Goa Verna plant and Farmingdale US plant inspected with zero Form 483 critical observations
- Global Regulatory Compliance Certifications – USFDA, UK-MHRA, TGA Australia, and EU-GMP accredited facilities
The Goa Verna plant and Farmingdale US facility operate under USFDA approvals, supplying high-volume OTC pain management and allergy products. The Southport facility in the UK provides localized manufacturing and packaging for European retail pharmacy clients.
Regulatory ANDA & Product Filings Pipeline of Marksans Pharma (FY2026)
Marksans Pharma maintains a growing portfolio of Abbreviated New Drug Applications (ANDAs) and Marketing Authorisations (MAs) across regulated markets.
- Cumulative US ANDA Filings Base – 55+ ANDAs filed with USFDA
- Total Approved US ANDAs – 45+ ANDA approvals received
- Cumulative UK & European Marketing Authorisations (MAs) – 300+ active MAs
- Annual R&D Expenditure Share – 2.5%–3.0% of Total Operating Revenue
Over 45 approved ANDAs support product dispatches in the United States, targeting pain relief, anti-allergy, and gastrointestinal care. Continuous R&D investments focus on developing complex soft-gelatin formulations and extended-release solid dosages.
Latest Quarterly Financial Performance of Marksans Pharma (Q1 FY2027)
Marksans Pharma recorded strong top-line revenue expansion and operating profit growth during the first quarter of FY2027.
- Consolidated Revenue from Operations – Rs 642.50 crore (+16.8% YoY)
- Consolidated Operating EBITDA – Rs 142.80 crore (+20.5% YoY)
- Operating EBITDA Margin – 22.22% (+68 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 96.40 crore (+22.8% YoY)
- Gross Profit Margin – 52.40% (+112 bps YoY)
First-quarter operating revenue rose 16.8% year-on-year to Rs 642.50 crore, supported by market share gains in US OTC channels and UK pharmacy contracts. Consolidated Net Profit After Tax reached Rs 96.40 crore, while operating EBITDA margins expanded to 22.22%.
Consolidated Annual Financial Performance of Marksans Pharma (FY2026)
Marksans Pharma achieved record full-year turnover expansion and net profitability for full financial year FY2026.
- Full Year Consolidated Revenue from Operations – Rs 2,485.40 crore (+18.2% YoY)
- Full Year Consolidated Operating EBITDA – Rs 538.20 crore (+21.4% YoY)
- Full Year Operating EBITDA Margin – 21.65% (+57 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 362.50 crore (+24.2% YoY)
- Return on Capital Employed (ROCE) – 22.8%
Full-year operating turnover crossed Rs 2,480 crore in FY2026, as consolidated Net Profit After Tax expanded 24.2% to Rs 362.50 crore. Performance was driven by volume growth in OTC products, Tevha Goa plant integration, and operational cost management.
Balance Sheet Structure & Financial Health Ratios of Marksans Pharma (Q1 FY2027)
Marksans Pharma operates a net-cash financial structure backed by strong operating cash flow conversion and low debt gearing.
- Debt to Equity Ratio – Net Cash Positive / Zero Debt (0.00x)
- Total Cash, Bank Balances & Surplus Investments – Rs 720.00 crore
- Total Consolidated Net Worth Base – Rs 2,150.00 crore
- Return on Equity (ROE) – 18.5%
- Working Capital Cycle – 108 days
The company closed Q1 FY2027 with zero long-term financial debt and Rs 720.00 crore in liquid surplus reserves. High return on capital employed of 22.8% reflects efficient asset utilization across global manufacturing facilities.
Capital Expenditure & Capacity Expansion Pipeline of Marksans Pharma (FY2027–FY2028)
Marksans Pharma executes capital allocation outlays to scale production lines at its Tevha Goa plant and expand US packaging infrastructure.
- Total Planned Multi-Year Capex Outlay – Rs 200–250 crore over FY2027–FY2028
- Tevha Goa Plant Expansion Outlay – Doubling solid oral and soft-gelatin capsule capacity (Target capacity: 8+ billion units)
- Farmingdale US Facility Automation – Installing automated high-speed bottle packaging and blister lines
- R&D Analytical Suite Upgrade – Scaling bio-equivalence and stability testing laboratories in Mumbai
- Funding Method – 100% funded through internal operational cash accruals and liquid reserves
Annual capital expenditure is budgeted at Rs 200–250 crore to double production capacity at the Tevha Goa plant and automate packaging in the US. Internal cash flows fund all planned facility modernizations without long-term debt additions.
Strategic Outlook & Management Commentary of Marksans Pharma (Q1 FY2027 Concall)
Management guidance outlines strategic priorities centered on Tevha plant commercialization, OTC channel deepening, and US margin expansion.
- Management targets achieving a 15%–18% revenue CAGR over the FY2027–FY2029 period.
- Operating EBITDA margins are guided to sustain within the 21.5%–23.0% corridor through high-margin OTC sales.
- Tevha Goa facility commercialization will double total group manufacturing capacity, driving long-term volume execution.
- US OTC business share will be expanded by launching 6–8 new soft-gelatin and liquid formulations annually.
- Capital allocation strategy will maintain a debt-free balance sheet while funding internal brownfield expansions.
Management anticipates rising demand for generic OTC pain relief and allergy medications in North America and Europe to support volume growth. Operational focus centers on commercializing new lines at the Tevha Goa site, driving R&D ANDA filings, and preserving balance sheet strength.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Marksans Pharma Q1 FY2027 Consolidated Financial Disclosures & Press Release (July/August 2026)
- Marksans Pharma Q4 & Full Year FY2026 Consolidated Financial Disclosures (May 2026)
- Marksans Pharma Q1 FY2027 Investor Presentation (July/August 2026)
- BSE Limited & National Stock Exchange of India (NSE) Corporate Filings for Marksans Pharma
- Ticker Finology Marksans Pharma Page
Disclaimer
The information presented above on Marksans Pharma has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Marksans Pharma page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.